Hills Bank & Trust Co. boosted its position in Johnson & Johnson (NYSE:JNJ) by 2.3% in the 3rd quarter, Holdings Channel reports. The firm owned 42,352 shares of the company’s stock after buying an additional 970 shares during the quarter. Johnson & Johnson accounts for approximately 1.4% of Hills Bank & Trust Co.’s portfolio, making the stock its 21st biggest position. Hills Bank & Trust Co.’s holdings in Johnson & Johnson were worth $5,479,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Phocas Financial Corp. increased its position in shares of Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $1,743,000 after acquiring an additional 125,161,066 shares during the period. Nuveen Asset Management LLC increased its holdings in Johnson & Johnson by 5,447.1% during the second quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock valued at $2,357,266,000 after buying an additional 16,619,550 shares during the period. Thoroughbred Financial Services LLC increased its holdings in Johnson & Johnson by 14,147.0% during the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after buying an additional 3,986,071 shares during the period. Renaissance Technologies LLC increased its holdings in Johnson & Johnson by 145.5% during the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock valued at $604,637,000 after buying an additional 2,572,695 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in Johnson & Johnson by 11.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after buying an additional 2,204,757 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.
Shares of JNJ stock opened at $127.70 on Monday. The company’s 50 day moving average is $130.45 and its 200 day moving average is $134.76. The company has a quick ratio of 1.04, a current ratio of 1.33 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The firm has a market cap of $359.38 billion, a price-to-earnings ratio of 15.53, a PEG ratio of 2.30 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.54%. The business had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. During the same period in the previous year, the company earned $2.05 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 8.65 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.98%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Several equities analysts recently issued reports on JNJ shares. Morgan Stanley reissued an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a report on Tuesday, August 27th. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective on the stock in a report on Friday, October 11th. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Tuesday, August 27th. Raymond James cut their price objective on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Finally, Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $151.18.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Most Volatile Stocks
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.